Material & Artwork Change Coordinator at Acadia Pharmaceuticals

Lisbon, Lisbon, Portugal

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, HealthcareIndustries

Requirements

1-2 years of experience in a similar role and/or one of the following areas: supply chain, planning, master data, regulatory affairs, quality or packaging site operations
Prior experience managing artwork changes; familiarity with an Artwork Management System is a strong asset
Ability to learn fast, curious mindset, interest in cross functional collaboration
Comfortable working with workflow management systems and Microsoft Office 365, able to coordinate the execution of workflows in a timely manner
Independent decision-making ability with excellent problem-solving skills
Team-oriented mindset with a proactive attitude and willingness to support colleagues and internal stakeholders as needed
Strong communication skills in English (French or additional languages are a plus)

Responsibilities

Analyse Finished Product Bill of Material (BoM) update requests from regulatory teams
Ensure compliant and timely implementation of component change requests
Develop and monitor component change planning, aligning regulatory requirements, global supply planning, and packaging site constraints
Track progress and ensure timely completion of workflows, escalate risks of supply delay
Collect and analyse launch information from various functions to assess business case viability to ensure timely readiness of New Product Launch
Analyse product portfolio to identify optimization opportunities and initiate discontinuation processes where applicable
Coordinate the artwork process with affiliates, production sites, global functions, and the graphic agency, ensuring a lean and right-first-time approach
Monitor delays in artwork approval and take necessary actions to maintain timelines
Collaborate with global packaging engineers to support technical integration and alignment across Ferring’s packaging sites, considering aspects such as packaging technology, serialization/aggregation capabilities, and printing feasibility
Serve as a key user of BLUE (Ferring’s artwork management system) and PLEX (Ferring’s SKU lifecycle system), contributing to system enhancements and process improvement

Skills

Bill of Material (BoM)

Component Change Planning

Artwork Management

Regulatory Compliance

Supply Chain Coordination

Manufacturing Coordination

Quality Standards

Product Launch

Change Management

Gastroenterology Products

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free